Application of Raw Corn Starch on Patients With Insulinoma

Status Recruiting

Clinical Trial Summary

This will be a prospective single-arm before-and-after clinical trial in which raw corn starch (RCS) will be first applied on patients with unoperated insulinoma. Nutritional intervention with supplementation of RCS will be initiated in 20 patients with suspected insulinoma to improve their hypoglycemia before the surgery. Duration of nutritional intervention, fasting blood glucose, lipid profile, weight change, BMI and other metabolic indices will be recorded and compared before and after the intervention.

Clinical Trial Description

Insulinoma is a rare disease which can cause recurrent hyperinsulinemic hypoglycemia, subsequent hyperphagia as well as weight gain. As only 50% ~ 60% of pharmacological therapy (diazoxide, somatostatin, etc) is effective to elevate blood glucose, the nutritional interventions play a role as an important supportive treatment to maintain glycemic stablization and control weight gain before the curative surgery. As the essential management for patients with glycogen storage disease (GSD), the extended release cornstarch has been proved superior to prevent hypoglycemia since 1980s. Its application has elevated GSD patients' quality of life and prolonged their survival. In view of its charicteristic of chronic release in gastrointestinal tract, we will for the first time try to utilize the raw corn starch (RCS) on patients with suspected insulinoma and evaluate its efficacy of improving hypoglycemia in such patients.

This will be a prospective single-arm before-and-after clinical trial. Nutritional intervention with supplementation of RCS will be initiated in 20 patients with suspected insulinoma to improve their hypoglycemia before the surgery. Duration of nutritional intervention, fasting blood glucose, lipid profile, weight change, BMI and other metabolic indices will be recorded and compared before and after the intervention. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03930368
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Rongrong Li
Phone	+8601069155550
Email	lirongrong0331@163.com
Status	Recruiting
Phase	N/A
Start date	April 15, 2019
Completion date	December 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02021604` - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma	Phase 1
Withdrawn	`NCT02108782` - Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT05034783` - [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients	Early Phase 1
Terminated	`NCT02273752` - Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer	Phase 2
Completed	`NCT00937079` - Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients	Phase 1
Recruiting	`NCT04185350` - Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma	Early Phase 1
Recruiting	`NCT00001276` - Diagnosing and Treating Low Blood Sugar Levels
Active, not recruiting	`NCT02121366` - EUS-guided Ethanol Ablation of an Insulinoma	N/A
Terminated	`NCT00084461` - Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00131911` - Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00005910` - Laparoscopy to Remove Pancreatic Tumors (Insulinomas)	N/A
Recruiting	`NCT03583528` - DOTATOC PET/CT for Imaging NET Patients
Withdrawn	`NCT04915144` - 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs	Phase 2
Recruiting	`NCT05523778` - A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct	N/A
Recruiting	`NCT02560376` - 68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis	Phase 0
Completed	`NCT01525082` - Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors	Phase 2
Completed	`NCT00655655` - Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00075439` - Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors	Phase 2
Terminated	`NCT04452396` - CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia	N/A
Active, not recruiting	`NCT01824875` - Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.